Teemu Niiranen
MD, PhD
tejuni@utu.fi ORCID identifier: https://orcid.org/0000-0002-7394-7487 |
Cardiovascular epidemiology; cohort studies; blood pressure; hypertension; blood pressure measurement
Teemu Niiranen, MD, PhD, is a physician-scientist and a clinical hypertension specialist with a track record of productivity in hypertension research, successful mentoring, international research grant procurement, and inter-institutional international collaborations. His research on hypertension in large population cohorts has led to >250 publications that are cited by the European, American, British, and Japanese clinical hypertension guidelines. These publications include first- or last-author articles in BMJ, Circulation, European Heart Journal, Nature Communications and JAMA Cardiology.
After finishing his PhD and clinical training, Dr. Niiranen received in-depth training in cardiovascular disease epidemiology and omics during a post-doctoral period at the Framingham Heart Study, the oldest and most prestigious cardiovascular cohort study in the world. After his post-doctoral period, he was selected as one of the new Group Leaders of the University of Turku Collegium of Science and Medicine and in 2020, the professor of internal medicine at the university. He is also employed as a Medical Specialist by the National Institute for Health and Welfare and chairs the work of the Cardiometabolic Clinical Expert Group of the FinnGen study, a project that has genotyped up to 500 000 unique Finnish blood samples and merged this genetic data with nationwide healthcare registers.
Dr. Niiranen has received young investigator awards from the American and Finnish Societies of Hypertension, and the American Heart Association. He is the past chair of the Finnish Hypertension Society and has mentored 12 PhD students. He is a co-author of the Finnish and European Society of Hypertension clinical hypertension guidelines.
In addition to general cardiovascular epidemiology, Dr. Niiranen's research has focused on the epidemiology of hypertension in large scale population cohorts. His studies particularly focused on home monitoring of blood pressure and more recently he has moved into examining the relation between hypertension and omics (genome, metagenome and metabolome).
Hypertension and clinical epidemioogy.
- Reply (2019)
- Journal of Hypertension
(B1 Non-refereed article in a scientific journal) - Risk prediction of atrial fibrillation in the community combining biomarkers and genetics (2019)
- European Heart Journal
(Other publication) - Sex Differences in the Cardiac Effects of Early-Onset Hypertension (2019)
- Hypertension
(B1 Non-refereed article in a scientific journal) - Sex-Specific Epidemiology of Heart Failure Risk and Mortality in Europe Results From the BiomarCaRE Consortium (2019)
- JACC: Heart Failure
(A1 Refereed original research article in a scientific journal) - Smoking is the strongest modifiable risk factor for mortality post coronary revascularisation (2019)
- European Journal of Preventive Cardiology
(B1 Non-refereed article in a scientific journal) - Statistical Workflow for Feature Selection in Human Metabolomics Data (2019)
- Metabolites
(A2 Refereed review article in a scientific journal ) - Verenpainetta ei vieläkään oteta vakavasti (2019)
- Lääkärilehti
(D1 Article in a professional journal) - Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants (2018)
- International Journal of Epidemiology
(A1 Refereed original research article in a scientific journal) - Electrocardiographic predictors of atrial fibrillation in nonhypertensive and hypertensive individuals (2018)
- Journal of Hypertension
(A1 Refereed original research article in a scientific journal) - Familial clustering of hypertensive target organ damage in the community (2018)
- Journal of Hypertension
(A1 Refereed original research article in a scientific journal)



